Screener
LB Pharmaceuticals Inc LBRX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| General and administrative | 7,459 | 3,008 |
| Total operating loss | (22,104) | (6,429) |
| Non-operating income | ||
| Interest income | 2,850 | 236 |
| Realized gain on sale of marketable securities, net | — | 119 |
| Gain on change in fair value of derivative instruments | 200 | 768 |
| Total non-operating income | 3,050 | 1,123 |
| Loss before income tax | (19,054) | (5,306) |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's interest income?
- LB Pharmaceuticals Inc (LBRX) reported interest income of $2.85M in Q1 2026.
- How has LB Pharmaceuticals Inc's interest income changed year-over-year?
- LB Pharmaceuticals Inc's interest income increased by 1107.6% year-over-year, from $236K to $2.85M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about LB Pharmaceuticals Inc's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude